Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo

被引：0

作者：

Schuler, M. ^{[1
,2
]}

Yang, J. C. -H. ^{[3
,4
]}

Planchard, D. ^{[5
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[2] Univ Hosp Essen, German Canc Consortium DKTK, Partner Site, Essen, Germany

[3] Natl Taiwan Univ, Dept Med Res, Taipei 10764, Taiwan

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Gustave Roussy, Dept Med Oncol, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期

关键词：

CANCER;

D O I：

10.1093/annonc/mdw144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1172 / 1173

页数：2

共 4 条

[1] What is the clinical impact of the LUX-Lung 5 trial? [J].

Addeo, A. .

ANNALS OF ONCOLOGY, 2016, 27 (06) :1171-1172

[2]

[Anonymous], J THORAC ONCOL S2

[3] Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer [J].

Jackman, David ;

Pao, William ;

Riely, Gregory J. ;

Engelman, Jeffrey A. ;

Kris, Mark G. ;

Jaenne, Pasi A. ;

Lynch, Thomas ;

Johnson, Bruce E. ;

Miller, Vincent A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :357-360

[4] Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial [J].

Schuler, M. ;

Yang, J. C. -H. ;

Park, K. ;

Kim, J. -H. ;

Bennouna, J. ;

Chen, Y. -M. ;

Chouaid, C. ;

De Marinis, F. ;

Feng, J. -F. ;

Grossi, F. ;

Kim, D. -W. ;

Liu, X. ;

Lu, S. ;

Strausz, J. ;

Vinnyk, Y. ;

Wiewrodt, R. ;

Zhou, C. ;

Wang, B. ;

Chand, V. K. ;

Planchard, D. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :417-423

← 1 →